SGM
COGT icon

Seven Grand Managers’s Cogent Biosciences COGT Stock Holding History

Seven Grand Managers’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Hold
35,000
– – 0.05% 151
2026
Q1 		$1.35M Hold
35,000
– – 0.09% 138
2025
Q4 		$1.24M Buy
+35,000
New +$984K 0.09% 129

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Seven Grand Managers's COGT Position: Q2 2026 in Review

Seven Grand Managers held its Cogent Biosciences (COGT) position steady in Q2 2026 at 35,000 shares worth $1.35M. The position accounts for 0.05% of the portfolio, ranked #151.

Seven Grand Managers first reported a position in COGT in Q4 2025 and has held it in 3 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Seven Grand Managers held 35,000 shares of Cogent Biosciences worth $1.35M as of Q2 2026.
  • Seven Grand Managers left its Cogent Biosciences share count unchanged in Q2 2026.
  • Cogent Biosciences made up 0.05% of Seven Grand Managers's portfolio in Q2 2026, its #151 holding.
  • Seven Grand Managers first reported a position in Cogent Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.